

# Luminary Therapeutics selected as a 2022/2023 Showcase Company in NIH/NCI's investor initiative program

*Luminary Therapeutics a clinical stage gamma delta allogeneic cellular therapy company.*

MINNEAPOLIS, MN, USA, July 19, 2022 /EINPresswire.com/ -- Luminary Therapeutics was selected as a 2022/2023 Showcase Company in NIH/NCI's investor initiative program. Luminary Therapeutics is a clinical stage allogeneic cellular therapy company. Its gamma delta expansion platform coupled with its non-viral cell engineering process is unique in the industry.



Luminary Therapeutics' novel ligand-based CAR designed to bind three targets is set to enter the clinic in the early Fall of 2022 to treat Mantle Cell Cancer and Multiple Myeloma with its LMY-920 Cell Therapy. This BAFF CAR-T product was developed by Reshmi Parameswaran, PhD, an assistant professor at the Case Western Reserve School of Medicine and a faculty member in the Division of Hematology and Oncology, Department of Medicine, and the Seidman Cancer Center at University Hospitals (UH) in Cleveland.

"This recognition by the NIH is a validation on the thoughtful work completed to bring this cell therapy into the clinic. Luminary achieved this clinical milestone in a short two year period attributable to our ability to manufacture a cell therapy with a significantly lower cost and reduced time to clinic via a non-viral gene modification manufacturing method," said Jeff Liter Luminary's CEO.

###

About Luminary Therapeutics, Inc.

Luminary is a clinical stage allogeneic cell therapy company focused on combining advanced receptor design with superior cell engineering to overcome antigen escape and T cell

dysfunction. Luminary was founded by the team from B-MoGen that achieved a successful 5X exit in only three years. We are seeking Series A financing with venture firms or strategic partners to support our 1st clinical trial and development of our disruptive Universal Receptor that can modulate antigen specificity.

For more information visit [www.luminarytx.com](http://www.luminarytx.com)

Media and Investor Relations

Contact: Jeff Liter

Telephone: 1.612.309.7653

Email: [j.liter@luminarytx.com](mailto:j.liter@luminarytx.com)

Jeff Liter

Luminary Therapeutics

+1 612-309-7653

[email us here](#)

Visit us on social media:

[LinkedIn](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/581123334>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2022 Newsmatics Inc. All Right Reserved.